Increased Responsiveness of Human Coronary Artery Endothelial Cells in Inflammation and Coagulation by Lakota, Katja et al.
Hindawi Publishing Corporation
Mediators of Inﬂammation
Volume 2009, Article ID 146872, 8 pages
doi:10.1155/2009/146872
Research Article
IncreasedResponsivenessofHuman CoronaryArteryEndothelial
Cellsin Inﬂammation andCoagulation
KatjaLakota,KatjusaMrak-Poljsak,Blaz Rozman, andSnezna Sodin-Semrl
Department of Rheumatology, University Medical Centre, Vodnikova 62, 1000 Ljubljana, Slovenia
Correspondence should be addressed to Snezna Sodin-Semrl, ssodin1@yahoo.com
Received 16 July 2009; Accepted 26 October 2009
Recommended by Hidde Bult
The eﬀects of anti-inﬂammatory plant extracts, such as black tea extract (BTE) and resveratrol (RSV) could modulate cell
activation leading to atherosclerosis, however there is little comparative information about how diﬀerent endothelial cell types
are aﬀected by these compounds. In order to compare human endothelial cells derived from diﬀerent origins (umbilical vein or
HUVEC, coronary artery or HCAEC, microvascular or HMVEC) and their interleukin-1β (IL-1β) responsiveness, IL-6 ELISA,
RT-PCR, tissue factor assay, and prostacyclin responses using 6-keto PGF1α ELISA were determined. The IL-1β-induced IL-6 levels
were dose-dependent with highest responses seen in HCAEC. Signiﬁcant inhibition of IL-1β responses was achieved with BTE and
RSV, with the largest decrease of IL-6 and TF seen in HCAEC. Prostacyclin levels were highest in HUVEC and were inhibited by
RSV in all cell types. The diﬀerences between the endothelial cell types could account for greater susceptibility of coronary arteries
to inﬂammation and atherogenesis.
Copyright © 2009 Katja Lakota et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
Coronary artery disease, as an important manifestation of
atherosclerosis, is one of the most frequent causes of death
and disability in the Western world [1]. It has been proposed
that inﬂammation is the driving force in atherosclerosis
[2, 3], and strong evidence supports the central role of
proinﬂammatory cytokines, such as interleukin-1β (IL-
1β) and interleukin-6 (IL-6) in these pathologies. Human
coronary artery endothelial cells (HCAEC) have previously
been shown to have a strikingly greater responsiveness than
human umbilical vein endothelial cells (HUVEC) [4].
The endothelium is considered a dynamic organ with
secretory, metabolic, immunologic roles, in addition to its
regulatory function of nutrient transport. Endothelial cells
from diverse environments are heterogenous with respect
to their surface phenotype, mRNA expression, and levels
of IL-6 and procoagulant proteins, such as tissue factor
(TF). Within the past decades, the majority of endothelial
proinﬂammatory/coagulation studies have been performed
on HUVEC, derived from a vascular bed not present in
the adult, making these cells an inappropriate model of
endothelial inﬂammation and coagulation [5, 6].
TF is a pivotal factor found associated with endothelial
cells within atherosclerotic plaques [7] that can transform
the endothelial cell membrane from an anticoagulant to a
procoagulant surface following vascular injury [8]. Unique
sensitivity of HCAEC to tumor necrosis factor α (TNFα)-
stimulated expression of adhesion molecules (as compared
to human aortic endothelial cells) [9] and greater suscep-
tibility of HCAEC to inﬂammatory stimuli, (as compared
to HUVEC and human dermal microvascular endothelial
cells (HMVEC)) [4] have been reported. Endothelial cells
contribute to homeostasis and vasodilation, also by releasing
prostacyclin (PGI2) known to inhibit platelet aggregation
and deposition [5]. However, no reports as far as we know,
have addressed the comparative inﬂuence of IL-1β on PGI2
release, TF activity, or IL-6 protein release from HCAEC
versus other endothelial cell types.
Previous epidemiological studies have suggested that
black and green tea consumption may have beneﬁcial
eﬀects on endothelial function and is associated with
a decreased risk of cardiovascular events [10–13]. Black
tea inhibited the proliferation of smooth muscle cells
involved in the development and progression of atheroscle-
rosis [14] and mechanisms for the beneﬁcial eﬀects of2 Mediators of Inﬂammation
Table 1: Primer sequences and PCR conditions.
Primer sequences Denat. t/T Anneal. t/T Extens. t/T No. ofcycles
β-actin sense 5 -ATC TGG CAC CAC ACC TTC TAC AAT GAG CTG CG–3 
1 min/94
◦C 1 min/59
◦C 1.5 min/72
◦C2 5
antisense 5 -CGT CAT ACT CCT GCT TGC TGA TCC ACA TCT GC–3 
IL-6 sense 5 -ATG AAC TCC TTC TCC ACA AGC GC-3 
1 min/94
◦C 1 min/51
◦C 1.5 min/72
◦C3 0
antisense 5 -GAA GAG CCC TCA GGC TGG ACT G-3 
TF sense 5 -ACT ACT GTT TCA GTG TTC AAG CAG TGA TTC-3 
1 min/94
◦C 1 min/52
◦C 1.5 min/72
◦C3 5
antisense 5 -ATT CAG TGG GGA GTT CTC CTT CCC AGC TCTG-3 
t/T: time and temperature, Denat.: denaturation, Anneal.: annealing, Extens.: extension.
tea including vasculoprotective, antioxidative, antithrom-
bogenic, anti-inﬂammatory, and lipid-lowering properties
of tea ﬂavonoids have been reported [11, 15–18]. Animal
studies conﬁrmed that black tea extract (BTE) has anti-
inﬂammatory activity [15], however, its eﬀects on diﬀerent
types of endothelial cells is still not clear.
The polyphenolic stilbene resveratrol (RSV) is found in
grape skins, red wine, and peanuts [19, 20]. Trans -RSV
has been shown to inhibit TF expression in vascular cells
and to act anti-inﬂammatory [21–23]. RSV also attenuated
TNFα-activated HCAEC through the NF-kB pathway [24].
However, it is still largely unknown how BTE and/or
RSV aﬀect IL-1β-stimulated inﬂammatory and coagulation
pathways in HCAEC, as a novel model system, compared to
HUVEC or other endothelial cell types.
So, our focus has been to elucidate the mechanisms
that could modulate IL-1β proinﬂammatory/procoagulant
responses in HCAEC. The speciﬁc objectives of this
study were to understand the inﬂuence of potential anti-
inﬂammatoryplantextracts,suchasBTEandRSV,onIL-1β-
induced primary HCAEC and to compare their IL-6, TF, and
prostacyclin responses with other types of endothelial cells.
2.MaterialsandMethods
2.1.Materials. LyophilizedhumanIL-1β (Invitrogen-Carls-
bad, California, USA), resveratrol and extract from black
tea (Sigma - Saint Louis, Missouri, USA) were reconstituted
according to manufacturer’s instructions to stock concentra-
tion and stored until usage at −20
◦Co r−80
◦C. The black
tea extract used in the current report is composed of more
than 80% theaﬂavins (theaﬂavin and theaﬂavin gallates).
The ﬁnal concentration of IL-1β was 1000pg/mL, resveratrol
40μmol/L, and the ﬁnal concentration of black tea extract
was 40μg/mL unless otherwise stated.
2.2. Cell Culture. HUVEC, HCAEC, and HMVEC were pur-
chased from Cambrex BioScience (Walkesville, Maryland,
USA). The cells were plated onto 12 or 6 well plates or
75cm2 ﬂasks (TPP, Trasadigen, Switzerland) at 37
◦Ci na
humidiﬁed atmosphere at 5% CO2. HCAEC and HMVEC
were grown in EGM-2M medium (Cambrex BioScience,
Walkesville, Maryland, USA) containing 5% fetal bovine
serum; for HUVEC we used EGM medium containing 2%
fetal bovine serum (Cambrex BioScience, Walkesville, Mary-
land, USA). For experiments, subconﬂuent cell cultures were
used between 4 and 6 passages in serum-free medium with
addition of stimulatory and/or modulatory substances for 24
hours, unless otherwise indicated. Prior to experiments, cells
were incubated in serum-free media for 2 hours.
2.3. Measurement of Secreted Interleukin-6 and Prosta-
cyclin Metabolite 6-Keto PGF1α. IL-6 from cell culture
supernatants was measured and analyzed by human IL-6
ELISA from BioSource International (Camarillo, California,
USA) according to manufacturer’s instructions. Enzyme
immunoassay (EIA) 6-keto PGF1α (Cayman diagnostica,
Michigan, USA) was used to measure the concentration
of nonenzymatically converted metabolite of prostacyclin
or PGI2 in cell culture supernatants with competitive EIA
according to the instructions of the manufacturer. 6-keto
PGF1α is a stable product of PGI2.
2.4. RNA Isolation and Reverse Transcription Polymerase
Chain Reaction (RT-PCR) Analysis. Before RT-PCR, total
RNA from endothelial cell cultures was isolated using Total
RNA Isolation System (Promega, USA) following manufac-
turer’s instructions. The purity and amount of RNA were
determined by measuring the OD at a ratio of 260 to
280nm. 1μg of total RNA were transcribed into DNA by
Reverse Transcription System (Promega, USA) and PCR was
performed for β-actin, IL-6, and TF (Table 1). β-actin was
used as a control for normalization.
2.5. Tissue Factor Activity Assay. Tissue factor activity was
measured following the Actichrome TF (American diag-
nostica, Stamford, Connecticut, USA) procedure. After cell
treatment in 12 well plates, the medium was removed and
150μL/wellofTBS/TritonX-100buﬀerwasadded.Cellswere
then scraped and frozen at −80
◦C for 15 minutes and then
thawed at 37
◦C. This freeze-thaw cycle was repeated twice.
Subsequently, cells were kept at 37
◦C for another half an
hour. Cell lysates were then mixed with Factor VIIa and
Factor X in 96 well plates. Following a 15-minute incubation
at 37
◦C ,S p e c t r o z y m eF X aw a sa d d e df o r2 0m i n u t e sa n dt h e
reaction was stopped with glacial acetic acid. The absorbance
at 405nm was read on the Tecan Sunrise Colorimeter. The
standardcurvewasconstructedfromprovidedstandardsand
corresponding sample concentrations were calculated.
2.6. Statistical Analysis. All experiments were repeated three
times and the mRNA expression studies were shown asMediators of Inﬂammation 3
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Figure 1: Dose dependent responses of HUVEC, HCAEC, and
HMVECtoIL-1β(0–2000pg/mL)asmeasuredbyELISAofreleased
IL-6 protein levels from cell supernatants. Results are expressed as a
mean of three separate experiments.
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Figure 2: Released IL-6 protein levels as measured by ELISA of
supernatants from HUVEC, HCAEC, and HMVEC incubated with
IL-1β (1000pg/mL) for 24 hours in the absence or presence of BTE
(40μg/mL) and RSV (40μM). Data represent the mean ± SD of
three separate experiments. ∗P<. 05 compared with IL-1β levels of
expression.
1 representative gel of two performed. Data are presented as
am e a n± standard deviation (SD). Means were compared
between the treated and control groups using Student’s t-
test. P values less than .05 were determined to be statistically
signiﬁcant.
3. Results
In order to determine the inﬂammatory/coagulation
responses of primary human endothelial cells, in particular
HCAEC, stimulated with diﬀerent doses of IL-1β,w e
measured released IL-6 protein (Figure 1). Semiconﬂuent
primary HUVEC, HCAEC, and HMVEC were incubated
in 6-well plates with increasing doses of IL-1β (from 0 to
2000pg/mL) for 24 hours in serum-free media. Released
protein levels of IL-6 were measured in supernatants by
ELISA, and in parallel, mRNA expressions of β-actin, IL-6,
and TF were determined using RT-PCR. A comparison
of released IL-6 protein levels in the endothelial cell types
showed highest levels coming from HCAEC (approximately
2-fold higher than from HUVEC) and the lowest from
HMVEC (Figure 1). The ﬁrst rapidly increased IL-6 protein
levels were seen at an IL-1β concentration of 500pg/mL in
HCAEC and HUVEC, in comparison to HMVEC where
responses were consistently low. The mRNA expression
results show that IL-6, as well as TF mRNA expression dose
dependently increased with IL-1β in all cell types (data not
shown).
To investigate the eﬀects of modulatory molecules on IL-
1β-stimulatedendothelialcells,wemeasuredtheIL-6protein
levels in the presence or absence of BTE and RSV. Both BTE
andRSVsigniﬁcantlyinhibitedIL-6proteinlevelsofHCAEC
(Figure 2). IL-1β-induced TF activity showed the highest
responseinHCAECandwasinhibited byBTEandRSVinall
three endothelial cell types (Figure 3(a)). The IL-1β-induced
mRNA expression of IL-6 and TF in all endothelial cell types
is down-regulated with BTE and RSV (Figure 3(b)).
To investigate the eﬀects of IL-1β on homeostasis of
endothelial cells, released prostacyclin PGI2 was measured
as 6-keto PGF1α in cell supernatants (Figure 4). To deter-
mine whether the responses were dose dependent, HCAEC,
HUVEC, and HMVEC were incubated with increasing
concentrations of IL-1β (Figure 4(a)). The highest responses
were shown in HUVEC, which were around 3-4 fold
higher than in HCAEC. PGF1α levels from IL-1β-stimulated
HMVEC were below the detection limit. Contrary to IL-
6 levels and TF activity, BTE addition did not cause inhi-
bition of IL-1β-stimulated prostacyclin release (Figure 4(b),
left panel). However, RSV abrogated IL-1β-induced 6-keto
PGF1α levels in all three cell types (Figure 4(b),r i g h t
panel).
4. Discussion
In this report, HCAEC were used as a model cell system,
shown to be highly responsive to IL-1β-stimulated IL-6
released protein levels, TF activity, and inhibition of these
by BTE and RSV. Studies on HCAEC reported in literature
have looked at diﬀerent stimulating molecules, such as IL-
1α and TNFα,a c t i v a t e dp r o t e i nC ,l i p o p o l y s a c c h a r i d e[ 25–
28], and their eﬀects on diﬀerent cytokine and chemokine
expression, indicating unique cell type patterns and/or levels
of expression.
Lakota et al. previously indicated that HCAEC dis-
play greater susceptibility to inﬂammation and potential4 Mediators of Inﬂammation
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Figure 3: (a) TF activity was measured in the indicated treatments. Data are presented as arbitrary units, which indicate fold-change above
background TF levels and were generated from the mean of three separate experiments. (b) mRNA expressions of β-actin, IL-6, and TF are
shown from HUVEC, HCAEC, and HMVEC incubated with IL-1β (1000pg/mL) in the absence or presence of BTE (40μg/mL) and RSV
(40μM). The treatments of cell cultures were background control (lane 1), IL-1β 1000pg/mL (lane 2), IL-1β + BTE (lane 3), IL-1β +R S V
(lane 4), BTE (lane 5), and RSV (lane 6). Results shown are from one representative experiment of two separate ones performed.
atherogenesis than HUVEC or HMVEC [4]. This is in
accord with IL-1β-stimulated HCAEC data indicated in this
report. Among the most accessible natural substances used
worldwide are black tea, green tea, and wine, which have
beensuggestedtobeimportantmodulatorsofcardiovascular
disease (CVD). Both black and green tea have shown acute
beneﬁcial eﬀects on aortic stiﬀness and wave reﬂections, as
reported by Vlachopoulos et al. [29]. Since aortic stiﬀness
a n dw a v er e ﬂ e c t i o n sa r em a r k e r so fC V Da n dp r o g n o s t i c
factors of cardiovascular risk, they are important parameters
to be studied in healthy individuals [29]. Many epidemio-
logical studies of ﬂavonoid consumption however have been
performed with mixed results. One possible explanation
for the lack of cardiovascular protection in some of the
studies is the diﬀerence in infusion time, stirring, leaf
size, and measurements in plasma/whole blood changes,
although diﬀerent brands and addition of milk did not
show signiﬁcant variances [30]. However, ﬂavonoids were
reported to bind to protein, which causes variations in
bioavailability and also results in changed biological activity
especially in the case of binding to speciﬁc receptors and/or
enzymes [31, 32]. However, overall, the evidence suggests
that individuals with the highest ﬂavonoid intake have
modestly reduced risks for CVD (as reviewed in Vita JA,
2005 [33]). For tea, this conclusion is supported by a meta-
analysiswith10cohortstudiesandsevencase-controlstudies
included, which suggested an overall reduction in CVD risk
of around 11% with consumption of 3 cups of tea per
day [34]. A meta-analysis was also performed recently on
the association between green or black tea consumption
and the risk of stroke [35]. Data from 9 studies involving
4378 strokes among 194965 individuals were pooled. The
authors conclude that although a randomized clinical trial
would be necessary to conﬁrm the eﬀect, this meta-analysis
suggeststhatregardlessoftheircountryoforigin,individuals
consuming 3 cups of tea per day had a 21% lower risk of
ischemic stroke than those consuming less than 1 cup per
day. In a large sample (6597 subjects) of the elderly (over 65
years), Debette et al. reported for the ﬁrst time that carotid
plaques were less frequent with increasing tea consumption
in women [36].
Usually 1g of tea is used for 100mL of infusion [30, 32].
In the process of manufacturing, the black tea leaf catechins
are allowed to oxidize into theaﬂavins which give the black
tea its characteristic colour and taste. The black tea ﬂavonoid
content accounts for 20%–30% catechins, 10% theaﬂavins
and 50%–60% thearubigins [37], and both catechins as well
astheaﬂavinshavebeenshowntoactascardio-protectantsinMediators of Inﬂammation 5
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Figure 4: (a) IL-1β dose-dependent prostacyclin release, as measured by 6 keto-PGF1α, from HUVEC, HCAEC, and HMVEC.
Concentrations of IL-1β were 0–2000pg/mL. Data represent the mean of three separate experiments. (b) PGF1α levels measured in the
indicated endothelial cell types treated with IL-1β (1000pg/mL) and/or BTE (40μg/mL) [left panel] or IL-1β (1000pg/mL) and/or RSV
(40μM) [right panel]. Data represent the mean ± SD of three separate experiments.
cardiomyocytes [38]. Thearubigins are poorly characterised
and the bioavailability of theaﬂavins is poorly understood
[37].
The present data in HUVEC, HCAEC, and HMVEC
indicate that BTE signiﬁcantly abrogates IL-1β-induced IL-6
protein released levels similarly to RSV (Figure 2), while also
decreasing both TF activity levels and expression (Figure 3).
However, BTE does not seem to have any eﬀects on IL-1β-
induced PGI2 in any of the three cell types (Figure 4(b),
left panel). These diﬀerences imply that cytokine-speciﬁc
processes and diﬀerential signaling pathways might be
involved. Since black tea consumption has been previously
associated with a decreased risk of cardiovascular events [10,
11], signaling events in response to BTE are relevant. Bovine
aortic endothelial cells when exposed to BTE showed eNOS
activitymediated through p38 MAPKand estrogenreceptors
leading to phosphatidylinositol 3-kinase/Akt pathway and
eNOS generation [39, 40] and vasorelaxation of aortic rat
rings [40].
RSV-mediated cardio-protection is achieved through the
preconditioning eﬀect and thus achieves a number of cardio-
protective functions (reviewed in [19]), such as eﬀecting
release and/or generation of inﬂammatory mediators and
attenuation of various soluble intercellular cytokines. RSV
functions in scavenging free radicals and inhibiting lipid per-
oxidation, up-regulation of inducible NO synthase, vascular
endothelial growth factor, kinase insert domain-containing
receptor, and endothelial NO synthase. Adenosine receptors
also have an important function in the RSV precondition-
ing.6 Mediators of Inﬂammation
Dealcoholized wine (1 cup) delivered in a single oral
dose to healthy subjects less than 40 years old was found
to increase endothelium-dependent vasodilation [41]. The
authors indicate that this adds support to the hypothe-
sis that antioxidant properties of red wine, rather than
ethanol, may protect against cardiovascular diseases, how-
ever more research is needed on subjects with coronary
heart disease. Usually the concentrations of RSV in cellu-
lar models of CVD protection are 0.1–100μmol/ L [42],
although some studies showed diﬀerent eﬀects in low/high
doses in enhancing proliferation and inducing apoptosis
[43].
When RSV in humans is absorbed around 75% is
excreted via feces and urine. Serum levels were independent
from meals and its lipid content [44], but RSV is rapidly
metabolized into glucuronides and sulfates [20], which stay
in the blood for 9 hours [45]. Biologic activity of metabolites
was not elucidated yet [20, 42], and it is suggested that
prolonged administration could lead to increased concen-
trations [42, 46]. It is necessary to apply caution when
interpreting the literature data translating concentrations of
RSV on potential cardiovascular eﬀects.
To our knowledge, this is the ﬁrst report to show the
eﬀects of RSV on IL-1β-induced IL-6 and TF responses in
HCAEC, which could serve in cardioprotective processes
similar to the ones described previously [24, 42, 47, 48].
RSV has been shown to inhibit TF (at 5–100μmol/L) in
HUVEC [21] at comparable concentrations to the 40μM
used in the present report, to reduce expression of adhesion
molecules on stimulated human saphenus vein endothelial
cells[49],toinhibitadhesionofactivatedplateletstocollagen
or ﬁbrinogen [50] and lower ICAM, VCAM [24, 51]. RSV
was also reported to enhance the inhibitory activity of PGI2
on platelet aggregation in low doses [52], as well as to inhibit
TNFα-induced NAD(P)H oxidase and NF-κBa c t i v a t i o n
and inﬂammatory markers (at 0.1–10μmol/L) [24, 42, 51],
similarly to our results. In porcine coronary arteries, short
term treatment with RSV signiﬁcantly inhibited MAPK
activities, with reduced phosphorylation seen of ERK1/2,
JNK-1 and p38 MAPK [53, 54], and STAT3 phosphorylation
[55]. RSV was also found to inhibit protein kinase C in 2μM
concentration [56].
The data shown in HUVEC (Figure 4) indicates a similar
level of IL-1β-stimulated PGI2 (measured using 6-keto
PGF1α) as shown by Olszanecki et al. [57]. All three cell
types HUVEC, HCAEC, and HMVEC indicate a similar
vasoregulatory role for IL-1β, while RSV addition abrogated
PGI2 levels (Figure 4(b), right panel).
RSV has also been shown to decrease the expression of
vasoconstrictor endothelin and increase eNOS in HUVEC,
which might counterbalance PGI2 inhibition [58]a n d
decrease NAD(P)H oxidase activity [59].
In conclusion, a growing body of evidence indicates
that inﬂammation not only provides the baseline for future
atherosclerotic events, but is a necessity for coronary plaque
formation and coagulation leading to thrombosis. The
unique responsiveness of HCAEC could account for the
greater susceptibility of coronary arteries to inﬂammation
and atherogenesis leading to cardiovascular pathology and
substances, such as BTE and RSV, also inﬂuence these eﬀects
at the cellular level.
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